Investegate |Novo Nordisk A/S Announcements | Novo Nordisk A/S: Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Investegate announcements from Novo Nordisk A/S, Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

Related Keywords

Germany ,United States ,Denmark ,United Kingdom ,Washington ,Italy ,France ,Spain ,Ludovic Helfgott ,Frankd Lee ,Novo Nordisk ,Holdings Inc ,Linkedin ,Twitter ,Gdev Inc ,Nasdaq ,Forma Therapeutics Holdings Inc ,Facebook ,Moelis Company ,Drug Administration ,Davis Polk Wardwell ,European Commission ,Centerview Partners ,Exchange Commission ,Youtube ,Novo Nordisk Investor Relations Department ,Goodwin Procter ,Forma Investor Relations Department ,Forma Therapeutics ,Rare Disease ,Forma Therapeutic ,Forma Therapeutics Board ,Davis Polk ,Fast Track ,Rare Pediatric Disease ,Orphan Drug ,Orphan Medicinal Products ,European Medicines Agency ,Forma Therapeutics Holdings ,Tender Offer Statement ,Recommendation Statement ,Investor Relations Department ,Investegate Announcements ,Investegate Company Announcements ,Novo Nordiska S ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,